

Media Coverage

Company: AusBiotech
Date: 5 August 2009
Publication: Biotech Daily
Page: na

Buchan

Business Strategy | Communication | Public Policy

BIOTECH DAILY

Biotech Daily is pleased to learn that Aspermont and Ausbiotech have formalized a commercial joint venture. Aspermont publishes Australian Biotechnology News.

Along with other publications conducting commercial ventures that create potential conflicts of interest in reporting standards, this initiative leaves Biotech Daily as the only truly independent and dedicated publication informing the life sciences sector.

Separate to the Aspermont-Ausbiotech arrangement, there is a principle in professional journalism that reporters do not undertake paid work for those on whom they report.

It is an old-fashioned value often missing at daily newspapers across the world.

When Biotech Daily's analyst Marc Sinatra undertakes work for a private client, he is barred from writing about that company for two years.

It is simply not 'independent' to be paid by a company and then claim reporting on that company is objective.

Biotech Daily provides free advice to subscribers and operates a confidential match-making service requiring payment of one bottle of Australian champagne if a deal is struck.

Biotech Daily's broad subscription base makes it beholden to no individual interest and we are free to report without fear or favor, something that very few mainstream publications can claim.

The arrival of Ausbiotech's arrangement with Aspermont effectively leaves Biotech Daily as the only source of comprehensive, independent information about our sector.

It would not be possible without you, our subscribers.

David Langsam, Editor